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SUMMARY
Tumor relapse is associatedwith dismal prognosis, but responsible biological principles remain incompletely
understood. To isolate and characterize relapse-inducing cells, we used genetic engineering and prolifera-
tion-sensitive dyes in patient-derived xenografts of acute lymphoblastic leukemia (ALL). We identified a
rare subpopulation that resembled relapse-inducing cells with combined properties of long-term dormancy,
treatment resistance, and stemness. Single-cell and bulk expression profiling revealed their similarity to pri-
mary ALL cells isolated from pediatric and adult patients at minimal residual disease (MRD). Therapeutically
adverse characteristics were reversible, as resistant, dormant cells became sensitive to treatment and
started proliferatingwhen dissociated from the in vivo environment. Our data suggest that ALL patientsmight
profit from therapeutic strategies that release MRD cells from the niche.
Significance
After initially successful chemotherapy, relapse frequently jeopardizes the outcome of cancer patients. To improve the
prognosis of ALL patients, treatment strategies that eliminate tumor cells at minimal residual disease (MRD) and prevent
relapse are required. Toward a better understanding of the underlying biology, we established preclinical mouse models
mimicking MRD and relapse in patients. Primary and surrogate MRD cells shared major similarities in expression profiles,
demonstrating the suitability of our model. MRD cells revealed major functional plasticity in vivo and treatment resistance
was reversible; MRD cells became sensitive toward treatment once released from their in vivo environment. Effective ther-
apeutic strategies might aim at dissociating persistent cells from their protective niche to prevent relapse in ALL patients.
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INTRODUCTION
Relapse represents a major threat for patients with cancer. After
initially successful treatment, rare tumor cells might survive and
re-initiate the malignant disease with dismal outcome. Acute
lymphoblastic leukemia (ALL) is associated with poor prognosis
in infants and adult patients and is the most frequent malignancy
in children (Inaba et al., 2013). In many patients, the majority of
ALL cells respond to chemotherapy but a minority display resis-
tance, survive therapy, and cause relapse with poor outcome
(Gokbuget et al., 2012).
Despite its clinical importance, basic biologic conditions
underlying relapse remain partially elusive. For example, it is un-
clear whether relapse-inducing cells exist before onset of treat-
ment or develop as result of therapy, and whether permanent
or reversible characteristics determine relapse-inducing cells
(Kunz et al., 2015). Of translational importance, understanding
basic mechanisms opens perspectives for effective therapies
to eradicate relapse-inducing cells.
Relapse-inducing cells, by their clinical definition, self-renew
and give rise to entire tumors indicating tumor-initiating poten-
tial, a typical characteristic of cancer stem cells (Essers and
Trumpp, 2010). In numerous tumor entities including acute
myeloid leukemia, cancer stem cells were identified as a bio-
logically distinct subpopulation that displays specific surface
markers, has leukemia-inducing potential in mice, and gives
rise to a hierarchy of descendant cells that lack such properties
(Bonnet and Dick, 1997; Visvader and Lindeman, 2008). In ALL,
however, many different subpopulations display stem cell prop-
erties; neither a stem cell hierarchy nor phenotypic markers
defining stem cells could be identified (Kong et al., 2008; le Vi-
seur et al., 2008; Rehe et al., 2013). Thus, up to now, stemness
represents an insufficient criterion to define the subpopulation
of relapse-inducing cells in ALL.
An additional feature of relapse-inducing cells is their treat-
ment resistance, as, again by definition, they survive chemo-
therapy and eventually give rise to relapse with decreased
chemosensitivity. Resistance against chemotherapy is closely
related to dormancy as chemotherapy mainly targets prolifera-
tion-associated processes that are inactive in dormant cells
(Clevers, 2011; Zhou et al., 2009). Dormant cells, by definition,
do not divide or divide very slowly over prolonged periods of
time, might survive chemotherapy, persist in minimal residual
disease (MRD), and give rise to relapse (Schillert et al., 2013;
Schrappe, 2014). Indeed, an increased frequency of non-
dividing tumor cells has been described in patients after chemo-
therapy for defined subtypes of ALL (Lutz et al., 2013).
So far, technical obstacles have hampered characterizing
phenotypic and functional features of relapse-inducing cells in
ALL in detail. Established ALL cell lines represent inappropriate
models as they display continuous proliferation. In patients,
relapse-inducing cells are very rare and defining cell surface
markers that reliably identify these rare ALL cells from the multi-
plicity of normal bone marrow cells remains intricate, at least in
certain ALL subtypes (Hong et al., 2008; Ravandi et al., 2016).
Moreover, primary ALL cells do not grow ex vivo, disabling their
amplification in culture.
An attractive possibility to experimentally study patients’
tumor cells in vivo is the patient-derived xenograft (PDX) model,
which uses immuno-compromised mice to expand tumor cells
from patients (Kamel-Reid et al., 1989). As shown previously,
PDX ALL cells retain important characteristics of primary ALL
cells (Castro Alves et al., 2012; Schmitz et al., 2011; Terziyska
et al., 2012). While PDX models are mostly used for preclinical
treatment trials (Gao et al., 2015; Townsend et al., 2016), we
used them here to study relapse-inducing cells in ALL.
RESULTS
To characterize the challenging subpopulation of relapse-in-
ducing cells in ALL, we used the individualized xenograft mouse
model as a preclinical model, molecular cell marking as an
unbiased approach, and in vivo dormancy as a functional bench-
mark. To mimic the heterogeneity of ALL, samples from nine
different ALL patients were studied including children and adults,
B cell precursor-ALL and T-ALL, first diagnosis, and relapse
(Table S1).
Molecular Marking Allows Unbiased, Sensitive Isolation
of Rare PDX ALL Cells
To study ALL growth starting very early after disease onset in the
PDX mouse model, the technical challenge consisted in reliably
enriching very low numbers of human ALL cells from mouse
bone marrow. As expression levels of endogenous surface anti-
gens across potentially relevant, but yet undefined, subpopula-
tions are unknown, we used lentiviral transduction for unbiased
molecular marking and in vivo imaging (Figure 1A).
PDX ALL cells were lentivirally transduced to express a
luciferase for in vivo imaging (Terziyska et al., 2012), an artificial
antigen (truncated nerve growth factor receptor [NGFR]) for
magneto-activated cell sorting (Fehse et al., 1997) and a red
fluorochrome for cell sorting by flow cytometry (Figures S1A
and S1B). Transgenes allowed effective and reliable enrichment
of minute numbers of PDX cells from mouse bone marrow in
this two-step procedure. Quantification of PDX cells isolated
with the magnetic-activated cell sorting (MACS)/fluorescence-
activated cell sorting approach closely correlated with other
methodsmonitoring leukemic proliferation, such as in vivo imag-
ing and flow cytometry-based quantification of leukemia cells
(Figure S1C). Quality controls showed that the procedure was
highly efficient and reliable with minor cell loss (Table S2).
The procedure enabled addressing basic questions with
translational potential in ALL biology. Homing capacity of PDX
cells to mouse bone marrow differed by more than two orders
of magnitude between the nine samples studied (Figure 1B).
Homing efficiency decreased significantly when smaller cell
numbers were injected (Figure S1D). These data argue in favor
of sample-specific characteristics determining homing, and
against the presence of a preformed, fixed number of leukemia
homing sites within the niche. Spontaneous growth of PDX
ALL cells in mouse bone marrow was logarithmic over the first
2 weeks of in vivo growth (Figures 1C and S1C). Growth slowed
down thereafter and as early as at 10% blasts in bone marrow,
when space restriction appears unlikely to be causative. Model
selection indicated overall logistic growth which is typical for
insufficient nutrient supply (Figure S1E). Thus, PDX ALL cells
show sample-specific homing followed by logistic growth in
mouse bone marrow.
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CFSE Staining Allows Reliable Monitoring of PDX ALL
Growth in Mice
Proliferation-dependent dyes such as bromodeoxyuridine (BrdU)
and carboxyfluorescein diacetate succinimidyl ester (CFSE)
remain stable in mice over several months, enabling the charac-
terization of a heterogeneous growth pattern in normal hemato-
poiesis (Takizawa et al., 2011). We adapted the use of these
dyes in PDX tumor models. As BrdU staining requires the perme-
abilization and destroying of cells, fluorescent CFSE was mainly
used as it allows flow cytometric enrichment of living cells for
functional experiments including re-transplantation. Loss of
CFSE was used to distinguish subpopulations of slowly and
rapidly growing cells (Figures 1D and S1F) that were called la-
bel-retaining cells (LRC) and non-label-retaining cells (non-LRC),
respectively (Takizawa et al., 2011). LRC were defined as those
cells that had undergone at most three CFSE bisections resem-
bling cell divisions (see the Supplemental Experimental Proced-
ures for details). Loss of CFSE tightly correlated with increase in
PDX cell numbers and loss of BrdU (Figures 1E and S1G) and
confirmed that PDX ALL cells grow in vivo, but not ex vivo (Fig-
ure S1H). Thus, CFSE staining represents a reliable approach to
monitor proliferation of PDX ALL cells in mice.
Figure 1. CFSE Staining Allows Reliable
Monitoring of PDX ALL Growth in Mice
(A) Experimental procedure of generating PDX
ALL cells expressing several transgenes, staining
with CFSE, and enriching rare transgenic, CFSE-
stained PDX cells from mouse bone marrow.
(B) Of each PDX sample, 107 triple transgenic PDX
cells were injected intravenously into mice and re-
isolated from the bone marrow 3 days later; each
dot represents data from onemouse, except that a
mean of eight mice plus SE is shown for samples
ALL-199 and ALL-265.
(C) 107 CFSE-stained PDX cells/mouse were in-
jected and PDX cells were quantified in up to 11
mice per time point; shown is mean and SE.
(D) Gating strategy defining LRC, non-LRC, and
others. MFI of CFSE at the start of the experiment
(3 days after cell injection) was divided by factor 2
to model bisections; upon no more than three bi-
sections, cells were considered as LRC, upon
more than seven bisections as non-LRC; inter-
mediate cells were considered as others.
(E) Similar experiment as in (C), except that the
donor mouse was fed with BrdU in the last 7 days
before cell harvesting. Each dot represents data
from one mouse.
See also Figure S1, Tables S1, and Table S2.
A Rare, Long-Term Dormant
Subpopulation Exists in ALL PDX
Cells
Importantly, CFSE staining disclosed the
existenceofa rare fractionofPDXALLcells
that hardly divided over prolonged periods
of time (Figure 2A). LRC, by definition, had
undergone no more than three cell divi-
sions within 21 days, during which the leu-
kemia burden had risen by several orders
of magnitude so that mice would succumb to leukemia within a
fewdays. Inall ninePDXALL samples studied, LRCwere identified
after prolonged periods of leukemic growth; (Figures 2B and S2A).
Thus, similarly to normal hematopoiesis (Trumpp et al., 2010),
PDX ALL contains a rare subpopulation of LRC. LRC might
resemble the dormant tumor cells described in ALL patients
(Figure S2B) (Lutz et al., 2013). As an advantage over work
with primary cells, our preclinical approach allows repetitive
work on pure, vivid LRC, which gave us the chance to function-
ally and phenotypically characterize this interesting population.
LRCLocalize to theEndosteum, butAreNot Enriched for
Stem Cells
Both normal hematopoietic stem cells and leukemia stem cells
were reported to preferentially localize close to the endosteum,
where a supportive niche might exist (Morrison and Spradling,
2008). We also found that LRCs preferentially localized close
to the endosteum (Figures 3A–3C and S3), suggesting that
they might use the same niche as normal hematopoietic stem
cells and cancer stem cells.
We therefore asked whether LRCmight resemble cancer stem
cells. To compare leukemia-initiating potential between LRC and
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non-LRC, we performed limiting dilution transplantation assays
and monitored engraftment by bioluminescence in a total of 83
mice (Table S3). To our surprise, we found highly similar stem
cell frequencies in LRC and non-LRC and similar engraftment
rates after transplantation of, e.g., ten cells per mouse (Fig-
ure 3D). The 95% confidence interval of the estimated frequency
of leukemia-inducing cells ranged between 1/19 and 1/84 cells
for LRC and between 1/40 and 1/179 cells in non-LRC of ALL-
265 (Table S3). Similar findings were obtained for ALL-199 (Table
S3). Thus, although only LRC display typical characteristics of
stem cells such as reduced proliferation rate and localization
close to the endosteum, LRC and non-LRC exhibited similar
leukemia-initiating potential.
LRC Survive Systemic Drug Treatment In Vivo
Dormant cells are known for their resistance against drug treat-
ment, complicating elimination by anti-cancer therapy (Essers
and Trumpp, 2010). We compared in vivo drug response of
LRC and non-LRCby transplanting CFSE-labeled PDXALL cells,
treating mice with systemic chemotherapy on day 7 and
analyzing surviving LRC and non-LRC on day 10 (Figure 4A).
Chemotherapy reduced the overall leukemic burden by over
90% (Figures 4B and S4A) and eradicated most non-LRC. As a
prominent difference, most LRC survived chemotherapy so
that LRC increased in relative proportions (Figures 4C–4E and
S4B–S4D). A 10- to 100-fold less efficient elimination of LRC
compared with non-LRC became obvious across all PDX ALL
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Figure 2. A Rare, Long-Term Dormant Subpopulation Exists in ALL PDX Cells
(A) 107 CFSE-stained PDX ALL-265 cells were injected into each of six mice; bioluminescence in vivo imaging was performed prior to quantifying LRC in one
mouse per time point; LRC numbers are indicated and summarized in the line graph as a mean of up to ten mice ± SE.
(B) Identification of LRC in PDX cells from all different ALL patients. Experiments were performed as in (A).
See also Figure S2.
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samples tested that were derived from either primary disease or
relapse, suggesting that this phenomenon is not restricted to a
certain disease stage. Treatment-surviving LRC harbored leuke-
mia-initiating potential as they gave rise to leukemias upon re-
transplantation at a kinetic similar to that of untreated LRC
(Figures 4F and S4E).
Taken together, LRC share the most important functional fea-
tures that impede the cure of cancer: (1) dormancy, (2) in vivo
drug resistance, and (3) leukemia-initiating potential. LRC might
thus serve as preclinical surrogate for relapse-inducing cells
in ALL.
Expression Profile of LRC Shows Distinct Changes to
Non-LRC
Wethenevaluatedwhether LRCadequately resemble challenging
cells in patients. For a broad, unbiased comparison between LRC
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Figure 3. LRC Localize to the Endosteum, but
Are Not Enriched for Stem Cells
(A) Immunohistochemistry of consecutive mouse bone
marrow femur sections 10 days after injection of CFSE-
stained PDX ALL-265 cells; mCherry (red; left panel)
indicates all PDX cells, CFSE (green; right panel)
indicates LRC.
(B) All sections from day 10 were quantified defining
the endosteal region as less than 100 mm from bone
matrix; shown is the median with upper/lower quartile
and maximum/minimum of two to three sections from
two femurs in two mice per data point; ***p < 0.001,
****p < 0.0001 by two-tailed unpaired t test.
(C) Kinetic for ALL-265 as mean ± SE; ***p < 0.01 by
two-tailed unpaired t test.
(D) Ten LRC or non-LRC were injected into each of 39
mice and engraftment was determined by in vivo im-
aging at day 75; each dot represents one mouse;
dashed line represents detection threshold (5 3 105
photons s!1); ns: not significant as determined by two-
tailed unpaired t test.
See also Figure S3 and Table S3.
and non-LRC, RNA sequencing (RNA-seq)
wasperformedonsingle cells andbulkpopula-
tions (Figure 5A). Data from single cells corre-
lated with data from bulk populations and
different ALL PDX samples showed similar
expression profiles (Figures S5A and S5B).
Preliminary expression arrays on pools of 40
LRC and non-LRC showed mainly similar re-
sults (data not shown).
Single LRC differed consistently from single
non-LRC as revealed by clustering differently
expressed genes (Figures 5B and Table S4)
and by a principle component analysis of the
most variable genes (Figure 5C). Single LRC
also had an overall reduced RNA content (Fig-
ure S5C), indicating a less active metabolism
that is a prerequisite of dormant cells. We
combined single-cell and bulk data of all six
sample pairs to identify differently expressed
genes (Table S5). Enrichment analysis re-
vealed that genes expressed less in LRC
were most strongly enriched in cell cycle and DNA replication
and that genes more expressed in LRC were most strongly en-
riched in cell adhesion (Figures 5D, S5D, and Table S6). Hence,
expression profiling of single cells and in bulk confirmed the
quiescent state of LRC and an LRC signature of at least 2-fold
differently expressed genes ranked by their significance (Figures
5E and Table S5) was used for further comparisons.
LRC Resemble MRD Cells in the PDX Mouse Model
Relapse often results from treatment-resistant tumor cells that
survive chemotherapy and persist at MRD. MRD cells contain
a major fraction of dormant tumor cells (Lutz et al., 2013).
Here, we hypothesized that LRC might represent surrogates
for MRD cells.
To experimentally test this hypothesis, we established a pre-
clinical model ofMRD for ALL-265 and ALL-199.When untreated
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control samples were harvested at advanced leukemia, they
contained a leukemic burden of "30% human blasts in mouse
bone marrow, mimicking the situation at diagnosis. Remaining
mice received a systemic treatment with conventional chemo-
therapeutic drugs over 2–3weeks (Figure 6A), which needs care-
ful dosing as supportive therapy is mainly unfeasible in mice. A
combination treatment of vincristine and cyclophosphamide
reduced tumor burden substantially according to in vivo imaging
(Figures 6B, 6C, and S6A). Postmortem analysis revealed that
chemotherapy had reduced leukemic burden by more than two
orders of magnitude to "0.1% leukemia cells in bone marrow.
This resembled not only complete morphologic, but also com-
plete molecular remission criteria (Figures 6D and S6B). MRD
cells revealed relapse-inducing potential as they re-grew in
mice when treatment was stopped (Figure S6C).
MRD cells were isolated from mouse bone marrow using ex-
pressed transgenes as above, and RNA sequencing of single
cells and bulk samples was performed. Resulting transcriptomes
showed marked differences between MRD and untreated con-
trol cells (Figure S6D). Enrichment analysis revealed significantly
reduced expression of MYC and E2F target genes in MRD
compared with untreated cells. Genes expressed less in MRD
cells were most strongly enriched in cell cycle and DNA replica-
tion, while genes expressed more in MRD cells were most
strongly enriched in cell adhesion (Figures 6E andS6E). This sug-
gests a dormant phenotype of MRD cells similar to the dormant
phenotype seen in LRC (Figure 5D). KEGG pathway analysis
Figure 4. LRC Survive Systemic Drug Treat-
ment In Vivo
(A) Each mouse was injected with 107 CFSE-
stained ALL-265 PDX cells and treated with buffer,
etoposide (ETO, 50 mg/kg, intraperitoneally [i.p.]),
or cyclophosphamide (Cyclo, 150 mg/kg, i.p.)
on day 7. Mice were euthanized on day 10; LRC
were analyzed and re-transplanted into secondary
recipients.
(B) Living PDX cells from mice in (A) were quan-
tified and presented as mean of each group (n =
4–5) ± SE.
(C) Original data for one representative mouse per
treatment.
(D) Mean of all four to five mice per treatment,
depicted as relative drug effect on LRC compared
with non-LRC (100%) ± SE; ****p < 0.0001 by two-
tailed unpaired t test.
(E) Mean relative proportion of LRC of total PDX
cells.
(F) LRC isolated were re-transplanted and mice
monitored by in vivo imaging; mean of each group
(n = 1–2) ± SE.
See also Figure S4.
highlighted that MRD cells were of
dormant nature and expressed increased
adhesion molecules (Figure S6E). Indeed,
single MRD cells clustered together with
single LRC in a principal component
analysis separated from non-LRC and
cells from untreated mice (Figure S6F).
Accordingly, the LRC signature (Figure 5E
and Table S5) was strongly enriched in MRD cells and genes in
MRD and LRC cells were similarly regulated compared with their
respective controls (Figure 6F). This suggests that LRC mimic
MRD cells in our preclinical mouse model.
LRC Resemble Primary MRD Cells from Patients
To relate these findings to the clinical situation, expression pro-
files from primary tumor cells from five children and two adults
with B cell precursor (BCP) ALL were profiled at diagnosis and
at MRD (Figure 7A and Table S7). Children and adults were
treated according to the BFM-2009 and GMALL-0703 protocols,
respectively, and MRD cells were enriched by flow cytometry at
days 33 and 71 of treatment, respectively. In adults, we chose
BCR-ABL-positive ALL and enriched the subpopulation of
StemB cells at MRD, as Lutz et al. (2013) had shown that these
cells exhibit a dormant phenotype. As dormancy in StemB cells
might have persisted for a long period during treatment in pa-
tients, LRC might especially resemble StemB cells at MRD. We
could obtain single-cell transcriptomes from one patient and
one bulk transcriptome from another patient. K-means clustering
and principal component analysis revealed that single StemB
cells clustered together with single LRC and MRD cells, while
single non-LRC clustered together with single untreated control
cells (Figures 7B and 7C). The bulk StemB sample was distinct
from diagnostic tumor cells of untreated adult patients with
BCR-ABL-positive ALL (Figure S7A). Although limited by small
cell and sample numbers, the data indicate that LRC resemble
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Figure 5. Expression Profile of LRC Shows Distinct Changes to Non-LRC
(A) Fifteen days after transplantation, ALL-265 LRC or non-LRC were isolated and single-cell mRNA-seq was performed in 15 LRC and 35 non-LRC.
(B) Hierarchical clustering and gene expression heatmap across the 500 most differentially expressed genes (false discovery rate [FDR] <0.01) in 15 LRC and 35
non-LRC single cells. Values are plotted relative to the average of non-LRC.
(C) Principal component analysis of the 500 most variable genes in all 50 single cells.
(D) Significantly enriched KEGG pathways (FDR <0.05) as determined by fixed network enrichment analysis (FNEA); bars show the number of significantly up- or
downregulated genes in the corresponding pathway and are ordered according to the enrichment score (ES).
(E) LRC signature genes (FDR < 0.05 and log2 fold-change >1) were derived from integrated bulk and single-cell RNA-seq analysis from six animals carrying either
ALL-265 or ALL-199 and are shown ranked by fold-change and colored by significance.
See also Figure S5, Tables S4, S5, and S6.
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Figure 6. LRC Resemble MRD Cells in the PDX Mouse Model
(A) 107 ALL-199 cells were injected into 19 mice; when 30% of bone marrow cells were human, PDX cells were enriched from five mice and used as untreated
control samples; cells of one mouse were subjected to single-cell sequencing; the remaining mice received buffer, vincristine (VCR, 0.25 mg/kg; n = 5),
cyclophosphamide (Cyclo, 100 mg/kg; n = 3), or a combination thereof (VCR + Cyclo; n = 6) weekly for 2 weeks; when VCR + Cyclo combination treatment had
reduced tumor burden to MRD (<1% human cells in bone marrow), PDX cells were enriched and cells of one VCR + Cyclo mouse were subjected to single cell
mRNA-seq.
(B) In vivo imaging data of three representative mice per group.
(C) Mean of each group ± SE; *p < 0.05, ***p < 0.001 by two-tailed unpaired t test; mice receiving buffer had to be euthanized after 1 week of treatment due to end-
stage leukemia.
(D) Percentage of PDX ALL cells in mouse bone marrow as determined by flow cytometry postmortem as mean ± SE; **p < 0.01, ***p < 0.001, ****p < 0.0001 by
two-tailed unpaired t test.
(E) MRD cells show reduced expression of MYC- and E2F-target genes in gene set enrichment analysis (GSEA) (Liberzon et al., 2015).
(legend continued on next page)
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the dormant subpopulation of StemB cells in adult ALL patients
at MRD.
This is also supported when comparing the LRC profiles with
further published transcriptomes. Genes differently expressed
in CD34-positive chronic myeloid leukemia cells (Graham et al.,
2007), in leukemia stem cells (Saito et al., 2010), in hematopoietic
stem cells (Eppert et al., 2011; Georgantas et al., 2004), as well
as in pediatric ALL cells with high risk of relapse (Kang et al.,
2010) were all significantly enriched in LRC versus non-LRC cells
(Figures 7D, S7B, and S7C).
To further analyze the similarity of LRC to MRD cells from
patients, we generated bulk transcriptomes of primary samples
from five children with BCP-ALL before the onset of treatment
and three matched MRD samples collected 33 days after the
onset of treatment. Expression profiles differed significantly be-
tween diagnosis and MRD (Figure 7E and Table S8) and MRD
cells regulated genes in the same direction as LRC compared
with their respective controls, as revealed by a significant
overlap of up- and downregulated genes (hypergeometric test,
p = 1.9 3 10!23) and by a significant enrichment of the LRC
signature (p < 0.001; Figure 7F). Finally, we combined these tran-
scriptomes with all bulk samples isolated from the LRC andMRD
mouse models and analyzed them unsupervised in a principal
component analysis (Figure 7G). The first principal component
separated all dormant and drug-resistant cells (PDX-LRC,
PDX-MRD, and primary MRD) from all control cells (PDX-non-
LRC, PDX untreated, and primary diagnosis).
In summary, we show that a distinct subpopulation of LRC
exists in our ALL PDXmodel that combines the unfavorable char-
acteristics of stemness, drug resistance, and dormancy. These
LRC show high similarities to MRD cells in our mouse model
and to MRD cells in ALL patients. Hence, LRC might represent
preclinical surrogates for relapse-inducing cells in patients and
could be used to develop therapeutic strategies to prevent
relapse.
Release from the Environment Induces Proliferation
in LRC
As the first step toward therapies, we studied whether unfavor-
able drug resistance and dormancy represented permanent or
reversible features in LRC. Dormancy and drug resistance might
exist as genuine, constant biological characteristics of a special
ALL subpopulation or as reversible functional phenotypes of
putatively every ALL cell depending on the context.
To address this question, LRC and non-LRC were dissociated
from their environment, isolated, and re-transplanted into recip-
ient mice (Figures 8A and S8A). When non-LRC were re-stained
with CFSE and re-transplanted at high numbers, they gave rise
to an identical LRC population as re-transplanted bulk cells (Fig-
ures 8B and S8A); transplantation of high cell numbers of LRC
was impossible, as only low numbers of LRC can be recovered
from mice. When low cell numbers were re-transplanted, LRC,
non-LRC, and bulk cells initiated identical leukemic growth in
mice as monitored by bioluminescence in vivo imaging (Figures
8C and S8A). These data indicate that dormancy represents a
reversible feature of LRC, as LRC lose their dormant nature
once they are retrieved from their specific environment and
transferred into a different surrounding.
Release from the Environment Sensitizes LRC and MRD
Cells for Drug Treatment
As dormancy emerged as a reversible phenotype, we asked
whether drug resistance might be equally reversible. Isolated
LRC and non-LRC or MRD and previously untreated cells from
the PDX mouse model were treated ex vivo with common ALL
chemotherapy drugs or drug controls. Here, the technical chal-
lenge lay in the very minor cell numbers of LRC and MRD that
can be isolated frommice and used for ex vivo experiments (Fig-
ure S8B). Co-culture with feeder cells resembling bone marrow
stroma reduced drug response in all samples, suggesting the in-
fluence of the bonemarrow environment on drug resistance (Fig-
ures S8C–S8F) (Tesfai et al., 2012). Ex vivo, neither LRC norMRD
cells displayed increased drug resistance compared with their
respective controls (Figures 8D and S8G).
Taken together, LRC and MRD cells showed a marked gain in
drug sensitivity ex vivo compared with in vivo after isolation from
the bone marrow environment. Both LRC and MRD cells lost
their enhanced drug resistance, distinguishing them from non-
LRC or untreated cells, once theywere retrieved from their in vivo
environment and cultured ex vivo (Figure 8E). Dormancy was
reversible in LRC and drug resistance was reversible in both
LRC and MRD cells. As LRC might represent surrogates for
relapse-inducing cells in patients, our data suggest that the inter-
action between LRC and their environment represents an attrac-
tive therapeutic target for preventing relapse. Relapse-inducing
cells might gain sensitivity toward treatment once mobilized
from their in vivo environment.
DISCUSSION
The present work aimed at a better understanding of the cells
that induce relapse in ALL and thereby limit prognosis of pa-
tients. We identified a rare, long-term dormant subpopulation
termed LRC exhibiting the adverse characteristics of dormancy,
in vivo drug resistance, and leukemia-initiating properties. LRC
highly resemble primary MRD cells from adult and pediatric pa-
tients with ALL. MRD cells require preferential eradication by
anti-leukemia treatment. LRC in preclinical models can now be
used as surrogates for relapse-inducing cells in patients for
developing therapies to prevent relapse. Upon removal from
their in vivo environment, LRC lost dormancy and drug resis-
tance, suggesting a reversible nature of adverse characteristics
and an important role for the interaction between ALL and the
environment. The data suggest that drug resistance and
dormancy are linked and represent an acquired stem-like
phenotype. Our data imply developing treatment approaches
that dissociate ALL cells from their protective niche to sensitize
them toward anti-leukemia treatment.
(F) GSEA was performed comparing LRC signature with transcriptomes of MRD versus untreated cells (mean of data for ALL-199; left panel). Scatterplot of fold-
changes for genes differentially expressed (FDR < 0.05) between both LRC versus non-LRC and MRD versus untreated control cells; grey area indicates LRC
signature (right panel).
See also Figure S6.
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Figure 7. LRC Resemble Primary MRD Cells from Patients
(A) Adult or pediatric ALL patients were treated according to GMALL-0703 or BFM-2009 protocols for 71 or 33 days, respectively; atMRD, the subgroup of StemB
cells (in samples from adults) or all remaining ALL cells (in samples from children) were enriched out of normal bone marrow; cells at diagnosis and at MRD were
subjected to RNA-seq.
(B) K-means clustering of gene expression values of 167 highly differentially expressed genes (FDR < 0.001) of all data from single cells.
(C) Principal-component analysis (PCA) of single cell transcriptomes using all shared expressed genes; each symbol indicates a single cell.
(D) GSEA comparing the LRC signature with signatures of leukemia stem cells (Saito et al., 2010) and dormant CD34-positive chronic myeloid leukemia (CML)
(Graham et al., 2007).
(legend continued on next page)
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Here, we provide a preclinical tool to study dormant human
ALL cells in vivo and show that long-term resting cells exist in
ALL. This fact was previously unknown, as primary patients’
samples allow quantifying non-cycling cells in a snapshot at a
given moment, but fail to distinguish between short- and long-
term resting cells (Lutz et al., 2013). As monitoring functionally
defined cellular subpopulations such as LRC in longitudinal
studies is still impossible in patients, our preclinical model en-
ables the gaining of insights into ALL biology that cannot be ob-
tained in patients: here the presence of long-term resting cells in
ALL. Beyond its use in preclinical treatment trials, PDX models
harbor major potential in basic research and enable unique in-
sights into disease biology.
The emergence of relapse is a complex process involving ge-
netic and non-genetic factors. Early relapse might be caused by
a putatively pre-existing clone with additional mutations respon-
sible for drug resistance, especially in adult patients. The genetic
stability of most cases of ALL suggests that many relapses may
not be mediated by mutational mechanisms. Late relapse might
be caused by persisting, dormant tumor cells in the absence of
additional mutations, and relapse cells often respond to the iden-
tical drugs used to treat the primary disease. LRC represent sur-
rogates for late relapse and relapse in the absence of additional
mutations, as often seen in children.
The fact that LRC exist might explain why ALL patients benefit
from maintenance therapy, even in prognostically favorable,
(E) All genes differentially expressed (padj < 0.05) between primary samples from five children before onset of treatment to three matched MRD samples 33 days
after onset of treatment.
(F) Scatterplot of fold-changes for genes differentially expressed between both LRC versus non-LRC and primary MRD versus primary diagnostic cells, grey area
indicates LRC signature (left panel); GSEA comparing the LRC signature with differentially expressed genes between primary MRD and primary diagnostic cells
(right panel).
(G) PCA of bulk samples transcriptomes using all shared expressed genes; each symbol indicates a single sample.
See also Figure S7, Tables S7, and S8.
Figure 8. Release from the Environment In-
duces Proliferation in LRC and Sensitizes
LRC and MRD Cells toward Drug Treatment
(A) From a first recipient mouse carrying CFSE-
stained ALL-199 cells, LRC, non-LRC, and bulk
cells were obtained at day 10; bulk cells and non-
LRC were re-labeled with CFSE, re-transplanted in
second recipient mice at high numbers, and re-
analyzed at day 10 using flow cytometry; bulk cells,
LRC, and non-LRC were re-transplanted at low
numbers into groups of mice and leukemia growth
was monitored over time.
(B) CFSE staining at day 10 in secondary recipient
mice receiving high cell numbers.
(C) Growth curve in secondary recipients;
mean ± SE; ns, no statistical significance by Kruskal-
Wallis test and Dunn’s multiple comparison test.
One out of two independent experiments is shown.
(D) Fourteen days after transplantation, LRC or non-
LRC were isolated and 500–800 cells treated ex vivo
for 48 hr with daunorubicin (DAU; 250 nM), mitox-
antrone (MITO; 675 nM), amsacrine (AMSA; 18 nM),
or etoposide (ETO; 300 nM). Spontaneous cell death
in the absence of cytotoxic drugs was 60%; a mean
of eight data points from three independent experi-
ments in triplicates or duplicates is shown for DAU
andMITO and one experiment in triplicates is shown
for AMSA and ETO. Four thousand untreated cells
and MRD cells were treated ex vivo for 48 hr with
15 mM ETO, 450 mM MITO, 300 nM VCR, or 500 nM
DOX. Cell death was measured by flow cytometry;
spontaneous cell death in the absence of cytotoxic
drugs was 33%; shown is one experiment in tripli-
cate; mean ± SE; ns, not significant, ***p < 0.001 by
two-tailed unpaired t test.
(E) Summary of ALL-265 data from Figure 4C (n = 5),
S6 (n = 3), and 8D (n = 3); ns, not significant, *p < 0.05
and ****p < 0.0001 by two-tailed unpaired t test.
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chemo-sensitive ALL subtypes. ALL patients are routinely treated
with oral low-dose chemotherapy from end of intensive chemo-
therapy until, e.g., 2 years after diagnosis, and maintenance ther-
apy improves patients’ prognosis (Schrappe et al., 2000). Low-
dose maintenance therapy might act by removing LRC-type
ALL cells with relapse-inducing potential that remained quiescent
over prolonged periods of time and turned on their cell cycle at
late time points in the months following intensive chemotherapy.
Tumor cells often display both dormancy and drug resistance.
It is unclear whether either dormancy or drug resistance is pivotal
in respect to the other, so that dormancy is a consequence of
resistance or vice versa (Blatter and Rottenberg, 2015). Our
two complementary mouse models show that LRC were defined
by their dormant nature and displayed drug resistance, while
MRD cells were defined by their ability to survive drug treatment
and displayed a dormant phenotype. Thus, both characteristics
might be equally sufficient to determine each other and coincide
interdependently.
Our study shows that ALL consists of functionally heteroge-
neous cells regarding proliferation rate and drug resistance,
similar to the functional heterogeneity shown in other tumor
entities (Kreso et al., 2013). As LRC did not substantially
participate in proliferation during growth of leukemia over
weeks, in our model LRC existed before onset of therapy
and were not developed as a consequence of treatment. As
both LRC and non-LRC contain similar amounts of stem cells,
but show different sensitivity toward drug treatment in vivo,
our data imply that stemness and drug resistance are not
directly connected in ALL.
So how does a rare subpopulation acquire the three clinically
challenging features dormancy, resistance, and stemness? LRC
might represent a cell subpopulation with genuinely different
biology harboring distinct intrinsic, constant characteristics, or
being an LRCmight represent a reversible, temporary, functional
phenotype depending on circumstances. In the first case, LRC
and non-LRC might be organized in a hierarchical way similar
to the known stem cell hierarchy existing in many tumors
including AML (Kreso and Dick, 2014). In the second case, ALL
cells might mimic the phenotypic reversibility of normal hemato-
poiesis, where long-term dormant hematopoietic stem cells start
cycling in response to stress for a defined period of time and turn
back into dormancy later (Trumpp et al., 2010).
Our data favor the second scenario as LRC exhibit their
specific characteristics as reversible, temporary, transient func-
tional phenotypes. Re-transplantation experiments showed that
formerly dormant LRC started proliferating as soon as they were
dissociated from their in vivo environment and transferred into
next recipient mice. Upon re-transplantation, LRC converted
into non-LRC, while certain non-LRC converted into LRC. Both
LRC and non-LRC thus harbored plasticity to switch between
slow and rapid proliferation depending on the current context.
This fact might explain the area of overlap between LRC and
non-LRC detected in single-cell RNA sequencing.
Besides proliferation, drug resistance also proved to be a tran-
sient characteristic. Drug-treatment experiments showed that
LRC lost their in vivo drug resistance upon ex vivo culture. The
discrepancy between drug sensitivity ex vivo and in vivo might
at least partly explain the limited predictability of ex vivo drug-
screening tests for the outcome of cancer patients (Wilding
and Bodmer, 2014). Thus, localization of LRC to the bone
marrow niche influences both dormancy and drug resistance.
These insights have translational implications. For diagnostics,
as LRC lose their clinically relevant characteristics upon release
from their niche, rapid sample processingmight becritical for reli-
able profiling, which represents a challenge in clinical routine
(Bacher et al., 2010). Our data at least in part explain the limited
power of in vitro assays using, e.g., proliferating cell lines, for
studies on MRD cells or primary leukemia cells for drug testing
in the absenceof feeders.Most importantly for putative treatment
strategies, the transient nature of the adverse characteristics of
LRCsuggests aiming at removingMRDcells from their protective
environment to sensitize them toward treatment (Essers et al.,
2009; Essers and Trumpp, 2010). The interaction between
MRD cells and their bone marrow niche represents a promising
target for therapeutic approaches to prevent relapse. Beyond
the tumor cell itself, its interaction with the environment repre-
sents a suitable therapeutic target. As a caveat, a persistent ther-
apeutic inhibition of the bone marrow niche might be required
over prolonged periods of time, as in principle each and every re-
maining non-LRC ALL cell could convert into a drug-resistant
LRC, as soon as it gets access to the protective niche.
At this point, we can only speculate which signals might deter-
mine whether an ALL cell behaves like an LRC or a non-LRC. In
theory, external as well as internal factors or conditions might be
influential; stimuli might be sent or received either stochastically
or within a well-regulated process. As our studies were restricted
to bonemarrow, the bonemarrow niche is a likely candidate for a
regulatory function and requires investigatory work (Raaij-
makers, 2011). Further research is required to address these
important questions. Obvious candidates for therapeutic inter-
vention are cell surface molecules expressed on LRC, the
inhibition of which might release cells from their environment.
Similarly, niche cells could be targeted to aim at reducing envi-
ronmental support.
Our study shows that ALL growing in vivo contains a rare
subpopulation of LRC that exhibits typical challenging adverse
characteristics of relapse induction, which proved to be of a
reversible nature. Our model might help to develop future anti-
leukemia treatment strategies allowing the eradication of the
precarious subpopulation of drug-resistant stem cells to prevent
relapse and improve the prognosis of patients with ALL.
EXPERIMENTAL PROCEDURE
Ethical Statements
Written informed consent was obtained from all patients and
fromparents/carers in the caseswhere the patients wereminors.
The study was performed in accordance with the ethical stan-
dards of the responsible committee on human experimentation
(written approval by Ethikkommission des Klinikums der Lud-
wig-Maximilians-Universit€at M€unchen, Ethikkommission@med.
unimuenchen.de, April 15, 2008, number 068-08) and with the
Helsinki Declaration of 1975, as revised in 2000.
All animal trials were performed in accordance with the current
ethical standards of the official committee on animal experimen-
tation under thewritten approvals by Regierung vonOberbayern,
poststelle@reg-ob.bayern.de, May 10, 2007 number 55.2-1-54-
2531-2-07 and August 8, 2010 number 55.2-1-54-2531-95-10.
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Enriching and Quantifying PDX and LRC from Mouse
Bone Marrow
PDX ALL cells were genetically engineered as described using
lentiviruses (Terziyska et al., 2012; Vick et al., 2015) to express
the transgenes’ truncated NGFR, a red fluorochrome, and lucif-
erase; cells were stained with BrdU and/or CFSE before re-
transplantation of fresh cells into mice.
For determining the fraction of dormant PDX ALL cells, mouse
bonemarrowwas harvested from numerous bones and enriched
for human PDX ALL cells using NGFR for MACS and the red fluo-
rochrome for flow cytometry cell sorting. LRC were discrimi-
nated from non-LRC using CFSE staining as shown in Figure 1D.
CFSE mean fluorescence intensity (MFI) was measured at day 3
after injection, when bleaching had ceased, and defined cells
before the onset of proliferation (‘‘0 divisions’’). Day 3 CFSE
MFI was divided by factor 2 to calculate CFSE bisections
mimicking cell divisions. Seven CFSE MFI bisections or more
were defined as entire loss of the CFSE signal characterizing
non-LRC. The LRC gate was set to include all cells harboring
high CFSE signal of below three bisections of the maximum
CFSE MFI (Schillert et al., 2013) (Figure 1D).
PDX Single-Cell RNA-Seq Library Construction
Single cells were isolated at 4#C and processed on the Fluidigm
C1 platform. In brief, 500 cells were loaded on the 10–17 mm
mRNA-seq IFC (Fluidigm) with External RNA Controls Con-
sortium spike-in controls. Cell lysis, reverse transcription, and
pre-amplification of cDNAwas done on-chip using the SMARTer
Ultra Low RNA Kit for C1 (Clontech). Harvested cDNA libraries of
the samples (2.5 mL) were used as input for tagmentation with the
Nextera XT Sample Preparation Kit (Illumina) at half the volume of
Illumina’s protocol. Barcoding PCRwas performed for 12 cycles.
Equal amounts of libraries were pooled.
RNA-Seq
Single-cell Smart-seq and bulk Smart-seq2 libraries were
sequenced at 1 3 50 bases on an Illumina HiSeq1500. SCRB-
seq and UMI-seq libraries were sequenced paired-end with 16
cycles on the first read to decode sample barcodes and unique
molecular identifiers and 50 cycles on the second read into the
cDNA fragment.
ACCESSION NUMBERS
RNA-seq data reported in this paper have been deposited in the NCBI’s GEO
database and are accessible through the GEO Series accession number GEO:
GSE83142.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and eight tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2016.11.002.
AUTHOR CONTRIBUTIONS
S.E. and E.Z.O¨. planned, performed, and analyzed the experiments and de-
signed the data presentation; C.Z., E.Z.O¨., S.P., and W.E. generated and
analyzed RNA-seq data, W.E. participated in writing the manuscript; S.T.
and C.C.A. established the mouse model, first detected LRC, and started their
characterization; M.G. started establishing the MRD PDX model; A.S. guided
the work of E.Z.O¨.; M.D. performed enrichment of pediatric MRD cells pro-
vided by R.P.G.; C.L., V.A.T., and T.E. performed enrichment of adult StemB
cells provided by H.P.; H.P.H. and K.So. performed immunohistochemistry
of primary bonemarrow biopsies; K.Sp. andW.H. provided primary adult sam-
ples of Figure S2; B.P., S.K., M.H., and B.K. performed and analyzed gene
expression array data; J.H. performed themathematical analysis of Figure S1E;
O.G. participated in designing the experiments, guiding the study, and writing
the manuscript; I.J. initiated and guided the study and wrote the manuscript.
ACKNOWLEDGMENTS
We thank Jean Pierre Bourquin and Beat Bornh€auser for providing engrafted
sample ALL-265 and Cornelia Eckert and the I-BFM study group for providing
the clinical data on sample ALL-265. We thank Markus G. Manz for helpful sci-
entific discussions, Hitoshi Takizawa for help in establishing CFSE staining,
Susanne Suhendra for sorting pediatricMRD cells, Volker Eckstein, Panagiotis
Gitsioudis, and Linda Manta for their help in sorting stemB cells, Michael Ha-
gemann and his team for excellent animal care, Lothar Strobl for help in array
analysis, Kai Ho¨fig for help with qPCR, Andreas Sendelhofert for establishing
immunohistochemistry, Annette Frank and Volker Groib for help in mice exper-
iments, Liliana Mura and Fabian Klein for technical support, and Michela Car-
let, Cornelia Finkenzeller, and Binje Vick for helpful discussions. The work was
supported by ERC Consolidator Grant 681524; Deutsche Jose´ Carreras
Leuk€amie-Stiftung (R 10/26); the Collaborative Research Centers 684 Molec-
ular Mechanisms of Normal and Malignant Hematopoiesis, project A22 and
1243 Genetic and Epigenetic Evolution of Hematopoetic Neoplasms, project
A05; the German Consortium for Translational Cancer Research (DKTK); Bet-
tina Br€au-Stiftung; and Dr. Helmut Legerlotz Stiftung (all to I.J.); Collaborative
Research Center 1243, project A14, to W.E.; project 07 to K.S., and project 08
to W.H.; the German Federal Ministry of Education and Research (BMBF)
within the Virtual Liver Project (grant no. 0315766) to J.H.; and the German
Research Foundation grants SPP1395/InKoMBio Busch 900/6-1 to B.K. and
DFG GI-540-3/1 to O.G.
Received: August 19, 2015
Revised: June 11, 2016
Accepted: October 31, 2016
Published: December 1, 2016
REFERENCES
Bacher, U., Kohlmann, A., and Haferlach, T. (2010). Gene expression profiling
for diagnosis and therapy in acute leukaemia and other haematologic malig-
nancies. Cancer Treat Rev. 36, 637–646.
Blatter, S., and Rottenberg, S. (2015). Minimal residual disease in cancer ther-
apy – small things make all the difference. Drug Resist Updat 21-22, 1–10.
Bonnet, D., and Dick, J.E. (1997). Human acute myeloid leukemia is organized
as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3,
730–737.
Castro Alves, C., Terziyska, N., Grunert, M., G€undisch, S., Graubner, U.,
Quintanilla-Martinez, L., and Jeremias, I. (2012). Leukemia-initiating cells of
patient-derived acute lymphoblastic leukemia xenografts are sensitive toward
TRAIL. Blood 119, 4224–4227.
Clevers, H. (2011). The cancer stem cell: premises, promises and challenges.
Nat. Med. 17, 313–319.
Eppert, K., Takenaka, K., Lechman, E.R., Waldron, L., Nilsson, B., van Galen,
P., Metzeler, K.H., Poeppl, A., Ling, V., Beyene, J., et al. (2011). Stem cell gene
expression programs influence clinical outcome in human leukemia. Nat. Med.
17, 1086–1093.
Essers, M.A.G., and Trumpp, A. (2010). Targeting leukemic stem cells by
breaking their dormancy. Mol. Oncol. 4, 443–450.
Essers, M.A., Offner, S., Blanco-Bose, W.E., Waibler, Z., Kalinke, U.,
Duchosal, M.A., and Trumpp, A. (2009). IFNalpha activates dormant haemato-
poietic stem cells in vivo. Nature 458, 904–908.
Fehse, B., Uhde, A., Fehse, N., Eckert, H.G., Clausen, J., Ruger, R., Koch, S.,
Ostertag, W., Zander, A.R., and Stockschlader, M. (1997). Selective
Cancer Cell 30, 849–862, December 12, 2016 861
immunoaffinity-based enrichment of CD34+ cells transduced with retroviral
vectors containing an intracytoplasmatically truncated version of the human
low-affinity nerve growth factor receptor (deltaLNGFR) gene. Hum. Gene
Ther. 8, 1815–1824.
Gao, H., Korn, J.M., Ferretti, S., Monahan, J.E., Wang, Y., Singh, M., Zhang,
C., Schnell, C., Yang, G., Zhang, Y., et al. (2015). High-throughput screening
using patient-derived tumor xenografts to predict clinical trial drug response.
Nat. Med. 21, 1318–1325.
Georgantas, R.W., 3rd, Tanadve, V., Malehorn, M., Heimfeld, S., Chen, C.,
Carr, L., Martinez-Murillo, F., Riggins, G., Kowalski, J., and Civin, C.I. (2004).
Microarray and serial analysis of gene expression analyses identify known
and novel transcripts overexpressed in hematopoietic stem cells. Cancer
Res. 64, 4434–4441.
Gokbuget, N., Stanze, D., Beck, J., Diedrich, H., Horst, H.A., Huttmann, A.,
Kobbe, G., Kreuzer, K.A., Leimer, L., Reichle, A., et al. (2012). Outcome of
relapsed adult lymphoblastic leukemia depends on response to salvage
chemotherapy, prognostic factors, and performance of stem cell transplanta-
tion. Blood 120, 2032–2041.
Graham, S.M., Vass, J.K., Holyoake, T.L., and Graham, G.J. (2007).
Transcriptional analysis of quiescent and proliferating CD34+ human hemo-
poietic cells from normal and chronic myeloid leukemia sources. Stem Cells
25, 3111–3120.
Hong, D., Gupta, R., Ancliff, P., Atzberger, A., Brown, J., Soneji, S., Green, J.,
Colman, S., Piacibello, W., Buckle, V., et al. (2008). Initiating and cancer-prop-
agating cells in TEL-AML1-associated childhood leukemia. Science 319,
336–339.
Inaba, H., Greaves, M., and Mullighan, C.G. (2013). Acute lymphoblastic
leukaemia. Lancet 381, 1943–1955.
Kamel-Reid, S., Letarte, M., Sirard, C., Doedens,M., Grunberger, T., Fulop, G.,
Freedman, M., Phillips, R., and Dick, J. (1989). A model of human acute
lymphoblastic leukemia in immune-deficient SCID mice. Science 246, 1597–
1600.
Kang, H., Chen, I.M., Wilson, C.S., Bedrick, E.J., Harvey, R.C., Atlas, S.R.,
Devidas, M., Mullighan, C.G., Wang, X., Murphy, M., et al. (2010). Gene
expression classifiers for relapse-free survival and minimal residual disease
improve risk classification and outcome prediction in pediatric B-precursor
acute lymphoblastic leukemia. Blood 115, 1394–1405.
Kong, Y., Yoshida, S., Saito, Y., Doi, T., Nagatoshi, Y., Fukata, M., Saito, N.,
Yang, S.M., Iwamoto, C., Okamura, J., et al. (2008). CD34+CD38+CD19+ as
well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal
capacity in human B-precursor ALL. Leukemia 22, 1207–1213.
Kreso, A., and Dick, J.E. (2014). Evolution of the cancer stem cell model. Cell
Stem Cell 14, 275–291.
Kreso, A., O’Brien, C.A., van Galen, P., Gan, O.I., Notta, F., Brown, A.M., Ng,
K., Ma, J., Wienholds, E., Dunant, C., et al. (2013). Variable clonal repopulation
dynamics influence chemotherapy response in colorectal cancer. Science
339, 543–548.
Kunz, J.B., Rausch, T., Bandapalli, O.R., Eilers, J., Pechanska, P., Schuessele,
S., Assenov, Y., Stutz, A.M., Kirschner-Schwabe, R., Hof, J., et al. (2015).
Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selec-
tion, acquisition of mutations and promoter hypomethylation. Haematologica
100, 1442–1450.
le Viseur, C., Hotfilder, M., Bomken, S., Wilson, K., Ro¨ttgers, S., Schrauder, A.,
Rosemann, A., Irving, J., Stam, R.W., Shultz, L.D., et al. (2008). In childhood
acute lymphoblastic leukemia, blasts at different stages of immunophenotypic
maturation have stem cell properties. Cancer Cell 14, 47–58.
Liberzon, A., Birger, C., Thorvaldsdottir, H., Ghandi, M., Mesirov, J.P., and
Tamayo, P. (2015). The molecular signatures database (MSigDB) hallmark
gene set collection. Cell Syst 1, 417–425.
Lutz, C., Woll, P.S., Hall, G., Castor, A., Dreau, H., Cazzaniga, G., Zuna, J.,
Jensen, C., Clark, S.A., Biondi, A., et al. (2013). Quiescent leukaemic cells ac-
count for minimal residual disease in childhood lymphoblastic leukaemia.
Leukemia 27, 1204–1207.
Morrison, S.J., and Spradling, A.C. (2008). Stem cells and niches:mechanisms
that promote stem cell maintenance throughout life. Cell 132, 598–611.
Raaijmakers, M.H. (2011). Niche contributions to oncogenesis: emerging con-
cepts and implications for the hematopoietic system. Haematologica 96,
1041–1048.
Ravandi, F., Jorgensen, J.L., O’Brien, S.M., Jabbour, E., Thomas, D.A.,
Borthakur, G., Garris, R., Huang, X., Garcia-Manero, G., Burger, J.A., et al.
(2016). Minimal residual disease assessed by multi-parameter flow cytometry
is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br. J.
Haematol. 172, 392–400.
Rehe, K., Wilson, K., Bomken, S., Williamson, D., Irving, J., den Boer, M.L.,
Stanulla, M., Schrappe, M., Hall, A.G., et al. (2013). Acute B lymphoblastic
leukaemia-propagating cells are present at high frequency in diverse lympho-
blast populations. EMBO Mol. Med. 5, 38–51.
Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S.,
Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y., et al. (2010).
Identification of therapeutic targets for quiescent, chemotherapy-resistant hu-
man leukemia stem cells. Sci. Transl Med. 2, 17ra19.
Schillert, A., Trumpp, A., and Sprick, M.R. (2013). Label retaining cells in can-
cer – the dormant root of evil? Cancer Lett. 341, 73–79.
Schmitz, M., Breithaupt, P., Scheidegger, N., Cario, G., Bonapace, L.,
Meissner, B., Mirkowska, P., Tchinda, J., Niggli, F.K., Stanulla, M., et al.
(2011). Xenografts of highly resistant leukemia recapitulate the clonal compo-
sition of the leukemogenic compartment. Blood 118, 1854–1864.
Schrappe, M. (2014). Detection and management of minimal residual disease
in acute lymphoblastic leukemia. Hematology 2014, 244–249.
Schrappe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W.D., Henze,
G., Gadner, H., Odenwald, E., and Riehm, H. (2000). Long-term results of four
consecutive trials in childhood ALL performed by the ALL-BFM study group
from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 14, 2205–2222.
Takizawa, H., Regoes, R.R., Boddupalli, C.S., Bonhoeffer, S., and Manz, M.G.
(2011). Dynamic variation in cycling of hematopoietic stem cells in steady state
and inflammation. J. Exp. Med. 208, 273–284.
Terziyska, N., Alves, C.C., Groiss, V., Schneider, K., Farkasova, K., Ogris, M.,
Wagner, E., Ehrhardt, H., Brentjens, R.J., zur Stadt, U., et al. (2012). In vivo im-
aging enables high resolution preclinical trials on patients’ leukemia cells
growing in mice. PLoS One 7, e52798.
Tesfai, Y., Ford, J., Carter, K.W., Firth, M.J., O’Leary, R.A., Gottardo, N.G.,
Cole, C., and Kees, U.R. (2012). Interactions between acute lymphoblastic leu-
kemia and bone marrow stromal cells influence response to therapy. Leuk.
Res. 36, 299–306.
Townsend, E.C., Murakami, M.A., Christodoulou, A., Christie, A.L., Koster, J.,
DeSouza, T.A., Morgan, E.A., Kallgren, S.P., Liu, H., Wu, S.C., et al. (2016).
The public repository of xenografts enables discovery and randomized phase
II-like trials in mice. Cancer Cell 29, 574–586.
Trumpp, A., Essers, M., and Wilson, A. (2010). Awakening dormant haemato-
poietic stem cells. Nat. Rev. Immunol. 10, 201–209.
Vick, B., Rothenberg, M., Sandhofer, N., Carlet, M., Finkenzeller, C., Krupka,
C., Grunert, M., Trumpp, A., Corbacioglu, S., Ebinger, M., et al. (2015). An
advanced preclinical mouse model for acute myeloid leukemia using patients’
cells of various genetic subgroups and in vivo bioluminescence imaging. PLoS
One 10, e0120925.
Visvader, J.E., and Lindeman, G.J. (2008). Cancer stem cells in solid tumours:
accumulating evidence and unresolved questions. Nat. Rev. Cancer 8,
755–768.
Wilding, J.L., and Bodmer, W.F. (2014). Cancer cell lines for drug discovery
and development. Cancer Res. 74, 2377–2384.
Zhou, B.-B.S., Zhang, H., Damelin, M., Geles, K.G., Grindley, J.C., and Dirks,
P.B. (2009). Tumour-initiating cells: challenges and opportunities for anti-
cancer drug discovery. Nat. Rev. Drug Discov. 8, 806–823.
862 Cancer Cell 30, 849–862, December 12, 2016
Cancer Cell, Volume 30
Supplemental Information
Characterization of Rare, Dormant,
and Therapy-Resistant Cells in Acute
Lymphoblastic Leukemia
Sarah Ebinger, Erbey Ziya Özdemir, Christoph Ziegenhain, Sebastian Tiedt, Catarina
Castro Alves, Michaela Grunert, Michael Dworzak, Christoph Lutz, Virginia A.
Turati, Tariq Enver, Hans-Peter Horny, Karl Sotlar, Swati Parekh, Karsten
Spiekermann, Wolfgang Hiddemann, Aloys Schepers, Bernhard Polzer, Stefan
Kirsch, Martin Hoffmann, Bettina Knapp, Jan Hasenauer, Heike Pfeifer, Renate
Panzer-Grümayer, Wolfgang Enard, Olivier Gires, and Irmela Jeremias
ALL-265
ALL-199
A
B
C D
Supplemental Data
exponential
cell division ! cell death"
AL
L-
26
5
8
6
4
2
6
4
2
n
u
m
be
r o
f
t-P
DX
 
ce
lls
 [lg
]
m
e
a
n
CF
SE
 
in
te
n
sit
y
[lg
]
AL
L-
19
9
8
6
4
2
6
4
2
n
u
m
be
r o
f
t-P
DX
 
ce
lls
 [lg
]
m
e
a
n
CF
SE
 
in
te
n
sit
y
[lg
]
AL
L-
23
3
0    5   10 15  20 25 0    5  10  15  20 25 0    5  10  15  20 25
5
4
3
2
1
8
6
4
2
0
n
u
m
be
r o
f
t-P
DX
 
ce
lls
 [lg
]
m
e
a
n
CF
SE
 
in
te
n
sit
y
[lg
]
time [days after cell injection]
 
 
data: dynamics
logistic
data: control
model
E F
H
G
Figure S1, related to Figure 1.
CFSE staining allows reliable monitoring of PDX ALL growth in mice.
(A) Lentiviral construct for equimolar expression of 3 transgenes; arrow indicates start of transcription; EF1α =
elongation factor 1-alpha promoter; mKate = red fluorescent protein cloned from sea anemone Entacmaea
quadricolor; NGFR = human low affinity nerve growth factor receptor lacking the intracellular signaling domain.
(B) Quality controls on enriched transgenic PDX ALL-265 or ALL-199 cells by flow cytometry or
bioluminescence in vivo imaging.
(C) 107 ALL-265 cells were injected into groups of mice and one mouse was sacrificed at each time point. In
vivo imaging was performed directly before cell harvesting and quantifying PDX cells by flow cytometry with
and without prior MACS selection; mean of each group +/- standard error.
(D) Different cell numbers of ALL-199 cells were injected in mice at and re-isolated after 3 days; each dot
indicates data from one animal.
(E) The measured numbers of PDX cells and the measured mean fluorescence intensities of CFSE were fitted
with three mechanistic ordinary differential equation models assuming: exponential growth; logistic growth
caused by a decreased rate of cell division at higher cell densities; and logistic growth caused by a increased
rate of cell death at higher cell densities. The measured data (red circles and crosses), the best fit (gray line)
and the noise related uncertainty intervals (gray shaded area) are depicted.
(F) No cells devoid of CFSE labeling are found in the LRC gate; flow cytometry analysis at day 0 of unlabeled
ALL-265 PDX cells.
(G) Controls for BrdU and CFSE stainings; BrdU indicates feeding of mice and cells with BrdU; BrdU-ab
indicates that cells were stained with the anti-BrdU antibody; “+” and “-” indicate that the procedures were
performed or not, respectively.
(H) To compere behavior of PDX cells in vivo and ex vivo, 107 ALL-265 cells were injected into groups of mice
and one mouse was sacrificed at each time point to isolate PDX cells (left panel); 107 fresh CFSE labeled ALL-
265 PDX cells per ml were cultured on MS-5 feeder cells ex vivo (right panel).
BCP=B-cell precursor; *when the primary ALL sample was obtained; §time of passaging through
mice refers to the time from injection of the sample until mice had to be sacrificed due to end stage
leukemia
sample
type of
ALL
disease 
stage*
age*
[years] sex cytogenetics
passaging 
time§
[days]
ALL-199 BCP-ALLpediatric
2nd
relapse 8 F
somatic trisomy 21; leukemic 
homozygous 9p deletion 42
ALL-233 BCP-ALLpediatric
initial 
diagnosis <1 M t(2;15)(p13;q15) 76 
ALL-265 BCP-ALLpediatric 1
st relapse 5 F hyperploidy with additional 6, 13, 14, 17, 18, 21, X chromosome 43
ALL-435 BCP-ALLpediatric
initial 
diagnosis <1 M MLL-ENL, t(11;19) 40
ALL-50 BCP-ALLpediatric
initial 
diagnosis
7 F BCR/ABL positive 45
ALL-177 BCP-ALLpediatric
initial 
diagnosis 8 F TEL/AML1 positive 130
ALL-230 T-ALLpediatric
initial 
diagnosis 4 M
t(11;14)(p32;q11);  
rearrangement of TAL1-gene 
with the T-cell receptor locus
35
ALL-256 BCP-ALL
adult
initial 
diagnosis 41 F
trisomy 8; BCR/ABL positive 
t(9;22)(q34;q11) 75
ALL-363 BCP-ALL
adult
initial 
diagnosis 65 M
BCR-ABL positive 
t(9;22)(q34,q11) 60
Table S1, related to Figure 1.
Clinical data of patients donating diagnostic ALL cells for
xenotransplantation and sample characteristics.
*1x108 mouse bone marrow cells were mixed with different numbers of ALL-265 PDX cells
expressing NGFR and mKate; MACS-based enrichment targeting NGFR-expressing cells was
followed by flow cytometry-based enrichment targeting mKate-expressing cells; §enrichment factor
was calculated as ratio from “number of mouse bone marrow cells” and “recovered number of cells”
mixed* recovered
mouse bone marrow 
cells
PDX cells number of cells % recovery enrichment 
Factor§
1x108 1,250 1,234 99 81,000
1x108 12,500 10,262 82 9,700
1x108 37,500 34,679 92 2,666
Table S2, related to Figure 1.
Two step procedure allows enrichment of minute numbers of
PDX cells from mouse bone marrow.
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Figure S2, related to Figure 2.
A rare, long-term dormant subpopulation exists in ALL PDX cells
growing in mice.
(A) 107 CFSE labeled ALL-199 cells/mouse were injected into 3 mice and PDX cells were enriched from
bone marrow of 1 mouse at each time point using MACS sorting targeting NGFR and FACS sorting
targeting mKate; LRC and non-LRC were quantified by flow cytometry. One representative out of at least
10 independent experiments is shown. All further PDX samples did not express transgenes. Here, 10% of
the entire bone marrow isolate was analyzed without a prior MACS enrichment step. Unstained cells
represent mouse bone marrow cells and non-LRC. Day = number of days after injection of CFSE-labeled
cells.
(B) Immunohistochemistry was performed using TdT to visualize all ALL blasts and Ki-67 to visualize
proliferating cells in the diagnostic BM biopsy from one 69 years old female patient with BCR/ABL positive
normal karyotype ALL; double staining (lowest panel) indicates frequent dormant ALL blasts as TdT
positive, Ki-67 negative cells. Hemalum staining was used for nuclei; scale bar represents 50 µm.
AFigure S3, related to Figure 3.
LRC localize to the endosteum in ALL-199.
(A) Immunohistochemistry of consecutive murine bone marrow femur sections 10 days after injection of
CFSE-stained PDX ALL-199 cells; mCherry (red) indicates all PDX cells, CFSE (green) indicates LRC.
(B) Kinetic for ALL-199; mean +/- standard error; * p<0.05; ** p<0.01 by two-tailed unpaired t-test.
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*LRC and non-LRC obtained 14 days after injection of CFSE labeled ALL-265 or ALL-199 cells
were transplanted into secondary recipient mice in limiting dilutions at numbers indicated;
bioluminescence in vivo imaging was performed repetitively at the indicated time points to
determine engraftment; LIC frequency was calculated using the ELDA software; CI = confidence
interval
sample number of cells injected per mouse*
time [days after injection]
20 28 41 48 62 75
ALL-265
LRC 333 0/2 0/2 0/2 0/2 2/2 2/2
100     0/5 0/5 0/5 0/5 2/5 3/5
10 8/19
LIC frequency 1/40 (CI = 95%; lower = 1/84, upper = 1/19)
non-LRC 3333 0/3 1/3 3/3 3/3 3/3 3/3
1000 0/5 0/5 2/5 4/5 5/5 5/5
333 0/5 0/5 0/5 0/5 4/5 4/5
100 0/5 0/5 0/5 0/5 2/5 2/5
10 8/20
LIC frequency 1/85 (CI = 95%; lower = 1/179, upper = 1/40)
ALL-199
number of cells 
injected per mouse
time [days after injection]
35 42 49 56 69 77
LRC 333 0/3 0/3 0/3 0/3 2/3 3/3
100     n.d. 0/4 0/4 0/4 1/4 3/4
LIC frequency 1/69 (CI = 95%; lower = 1/209, upper = 1/23)
non-LRC 1000 1/5 3/5 5/5 5/5 5/5
333 0/3 2/3 2/3 3/3 3/3 3/3
100 0/4 1/4 1/4 3/4 4/4 4/4
LIC frequency 1/100 or higher
Table S3, related to Figure 3.
LRC and non-LRC harbor similar numbers of leukemia
initiating cells (LIC).
BA
C
D
E
Figure S4, related to Figure 4.
LRC survive systemic drug treatment in vivo.
Mice were injected with 107 CFSE-labeled ALL PDX cells/mouse, were treated on day 7 and sacrificed on
day 10; LRC and non-LRC were analyzed and re-transplanted into 1-2 secondary recipient mice at 2,000-
5,000 LRC per mouse.
(A) Numbers of PDX cells isolated from mice with and without prior systemic drug treatment; mean of each
group (n=8-11) +/- standard error.
(B) For ALL-199, a second relapse, 11 mice were treated with a single application of vincristine (VCR, 1.5
mg/kg i.v.), 8 mice were treated with a single application of etoposide (ETO, 75 mg/kg i.p.) and 8 control
mice received buffer; shown are original data of representative mice.
(C) Quantification in all mice per group depicted as mean of relative drug effects on LRC compared to non-
LRC (100%) +/- standard error. For ALL-50, a sample obtained at initial diagnosis, drugs were applied daily
over 3 days and 2 mice were treated with cytarabine (AraC, 150 mg/kg i.p.), 2 mice with ETO (33 mg/kg
i.p.), 2 mice with amsacrine (Amsa, 25 mg/kg i.p.) and 2 mice with epirubicine (EPI, 25 mg/kg i.p., single
application). For ALL-435, another sample obtained at initial diagnosis, drugs were applied daily over 3
days and 2 mice were treated with ETO (33 mg/kg, i.p.), 2 mice with Amsa (25 mg/kg i.p.) and one mouse
with EPI (25 mg/kg i.p., single application). ** p< 0.01, *** p<0.001, **** p<0.0001 by two-tailed unpaired t-
test.
(D) Mean relative proportion of LRC in total PDX cells with and without treatment.
(E) To study their stem cell potential, LRC of ALL-199 LRC were isolated after treatment, re-transplanted
and growth monitored by in vivo imaging mean of each group (n=1-2) +/- standard error. Imaging pictures
from dpi 60 (ctrl, VCR) and dpi 108 (ETO).
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Figure S5, related to Figure 5.
Expression profile of LRC shows distinct changes to non-LRC.
15 days after transplantation of CFSE labeled PDX cells, LRC and non-LRC were subjected to RNA
sequencing. For ALL-265, high quality single cell mRNA seq profiles were obtained from 15 LRC and 35
non-LRC cells. To combine single-cell and bulk RNA-seq data, median count data of single-cell
experiments were summarized as a single expression profile for each LRC and non-LRC.
(A) Hierarchical clustering and gene expression heatmap across the 500 most differentially expressed
genes comparing LRC and non-LRC in ALL-199 (p < 0.01).
(B) Comparison of Transcript Per Million (TPM) expression values between bulk versus single-cell ALL-265
(upper) and ALL-265 versus ALL-199 (lower).
(C) Quantification of expressed genes per cell (TPM > 1) in LRC versus non-LRC according to single-cell
RNA-seq of ALL-265; shown is the median with upper/lower quartile and maximum/minimum, outliers are
shown as dots.
(D) Gene set enrichment analysis for indicated KEGG pathways and the genes differentially regulated in
LRC versus non-LRC.
LRC non-LRC
Table S4, related to Figure 5.
List of 500 most differentially expressed genes between LRC
and non-LRC in single cell RNA sequencing of ALL-265
Provided as an Excel file.
Table S5, related to Figure 5. Integrated LRC signature.
Provided as an Excel file.
Table S6, related to Figure 5.
KEGG pathways enriched with LRC versus non-LRC
differentially expressed genes in combined analysis
Provided as an Excel file.
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Figure S6, related to Figure 6.
Characterization of cells at minimal residual disease.
(A-B) 107 ALL-265 cells were injected into 28 mice; when 40 % of bone marrow cells were human, therapy
was started using vincristine (VCR, 0.25 mg/kg; n=4) or cyclophosphamide (Cyclo, 100 mg/kg; n=4) or a
combination thereof (VCR+Cyclo; n=12), weekly for 3 weeks; VCR+Cyclo combination treatment had
reduced tumor burden to minimal residual disease (MRD; < 1% human cells in bone marrow).
(A) Mean of each group +/- standard error; * p<0.05, **** p<0.0001 by two-tailed unpaired t-test; mice
receiving buffer had to be sacrificed after two weeks of treatment due to end stage leukemia.
(B) Percentage of PDX ALL cells in mouse bone marrow as determined by flow cytometry post mortem as
mean +/- standard error; * p<0.05, ** p<0.01, **** p<0.0001 by two-tailed unpaired t-test.
(C) To study their behavior after release of treatment pressure, ALL-199 cells were injected into 4 mice per
group which were repetitively monitored by in vivo imaging; at substantial tumor burden, mice were treated
with Vincristine (VCR) 0.4 mg/kg and left untreated thereafter; mean of each group +/- standard error.
(D-F) ALL-199 cells were injected into 19 mice; when 30 % of bone marrow cells were human, 5 untreated
samples were harvested and one mouse were subjected to single cell sequencing; remaining mice
received either buffer or vincristine (VCR, 0.25 mg/kg; n=5) or cyclophosphamide (Cyclo, 100 mg/kg; n=3)
or a combination thereof (VCR+Cyclo; n=6) weekly for 2 weeks; when VCR+Cyclo combination treatment
had reduced tumor burden to minimal residual disease (MRD; < 1% human cells in bone marrow), cells
from the 6 VCR+Cyclo mice were isolated and one mouse were subjected to single cell sequencing.
(D) Hierachical clustering and gene expression heatmap across the 500 most differentially expressed
genes between MRD cells and untreated cells in ALL-199 single cell RNA sequencing (MRD cells n=90;
untreated cells n=32; p < 0.01; for gene annotation see Table S7).
(E) Significantly enriched KEGG pathways (p < 0.05) in MRD cells versus untreated cells as determined by
geneset enrichment analysis.
(F) Principle component analysis of transcriptomes of 32 untreated control ALL-199 single cells and 90
MRD cells together with single cell data from LRC and non-LRC as in Figure 5C.
AC
Figure S7, related to Figure 7.
LRC resemble primary MRD cells from patients.
(A) Principal component analysis of the bulk adult StemB sample compared to 3 bulk diagnosis samples of adult
patients with BCR-ABL positive ALL.
(B) Gene set enrichment analysis of genes differentially expressed in LRC versus non-LRC and published
signatures; HSC signature I = Georgantas et al., 2004; HSC signature II = Eppert et al., 2011 (left panel).
Principal component analysis (PCA) of ALL-265 single cells on the basis HSC marker genes (Eppert et al., 2011)
(right panel).
(C) Geneset enrichment analysis for a published gene signature prognostic for ALL with high risk of relapse
(Kang et al., 2010).
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study
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flow 
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stage
after 
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tion II
day of
MRD
measure-
ment§
BM 
blasts 
at 
MRD 
(%)$
sort
1  38 F GMALL 0703
BCR-
ABL na VHR CR 71 0.24 StemB*
2 39 M GMALL 0703
BCR-
ABL na VHR CR 71 0.32 StemB*
1 4 F BFM 2009
ETV6/
RUNX1 MR MR na na na
CD19+, 
CD10+++, 
CD20-
2 3 F BFM 2009
ETV6/
RUNX1 MR SR na na na
CD19+,
CD99bright, 
CD10+++
3 5 M BFM 2009 HD MR HR na 33 0.69
CD19+, 
CD10+, 
CD123+
4 18 M BFM 2009
B 
OTHER MR HR na 33 1.10
CD19+, 
CD10++, 
CD45-/dim
5 3 F BFM 2009 HD MR MR na 33 0.13
CD19+, 
CD10++, 
CD20dim
#age at diagnosis in years; F=female; M=male; GMALL=German Multicenter ALL Study Group;
BFM=Berlin-Frankfurt-Münster; HD=high hyperdiploid karyotype; RG=risk group; na=not
applicable; MR=medium risk; VHR=very high risk; SR=standard risk; HR=high risk; &therapy
risk group (RG) assignment; §days after onset of treatment; BM=bone marrow; $in BCR-ABL
positive samples, MRD was quantified by PCR using the BCR-ABL/ABL ratio; *StemB cells are
CD19+, CD34+, CD38-/low according to Lutz et al., 2013; Hong et al., 2008; Castor et al., 2005
Table S7, related to Figure 7.
Clinical data from BCP ALL patients of transcriptomes at
diagnosis and/or MRD.
Table S8, related to Figure 7.
List of most significantly differentially expressed genes
between primary samples from 5 primary ALL diagnosis and 3
MRD samples after 33 days of treatment.
Provided as an Excel file.
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Figure S8, related to Figure 7.
Identical growth behavior upon re-transplantation and identical ex vivo
drug sensitivity in LRC versus non-LRC.
(A) Upper panel shows experimental procedure; ALL-265 cells were amplified in donor mice, CFSE labeled, re-
transplanted into primary recipients and re-isolated after 14 days (left lane). Cells were separated into LRC
(middle lane) and non-LRC (right lane) and re-transplanted into secondary recipients which were imaged after 62
days (lower row). non-LRC were additionally re-labeled with CFSE and re-transplanted at high numbers which
was unfeasible for LRC due to their minor abundance (middle panel).
(B) 500 or 100,000 freshly isolated non-LRC (ALL-265) were stimulated ex vivo for 48 hours with the following
cytotoxic drugs: amsacrine (AMSA; 18 µM), daunorubicine (DAU; 250 nM); etoposide (ETO; 30 µM) and
mitoxantrone (MITO; 675 nM); shown is one experiment in triplicates +/- standard error; ns = not significant by
two-tailed unpaired t-test. Specific cell death was determined by DAPI staining and specific cell death calculated
thereof.
(C-F) Freshly isolated PDX cells were seeded in triplicates in the presence or absence of irradiated MS-5 cells
expressing the blue fluorochrome mtagBFP. Cells were stimulated for 48-72 hours and all cells per well were
removed by trypsin digestion and analyzed by flow cytometry. * p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001
by two-tailed unpaired t-test. SCD = spontaneous cell death in the absence of cytotoxic drugs.
(C) Feeder cells were excluded by gating on non-blue/mtagBFP-expressing cells; living cells were quantified in
absolute and relative amounts using either forward/side scatter analysis or propidium iodide staining with similar
results.
(D, E) 700-1,900 fresh LRC or non-LRC were stimulated with the following drugs: Etoposide (ETO; 3 µM) or
mitoxantrone (MITO; 0.45 µM) for ALL-265 and etoposide (ETO; 15 µM) or doxorubicine (DOX; 0.5 µM) for ALL-
199. E shows results obtained by forward sideward scatter analysis, F shows results obtained by propidium
iodide (PI) staining as well as absolute number of surviving cells as estimated in forward/side scatter analysis.
Shown are mean of up to 3 independent experiments; +/- standard error.
(F) 100,000 unsorted PDX ALL-265 were stimulated with vincristine (VCR; 0.3 µM), daunorubicine (DAU; 0.25
µM), doxorubicine (DOX; 0.5 µM), mitoxantrone (MITO; 0.45 µM), epirubicine (EPI; 0.4 µM) and etoposide
(ETO; 3 µM) for 48 hours; 100,000 unsorted PDX ALL-199 were stimulated with vincristine (VCR; 0.03 µM),
daunorubicine (DAU; 0.25 µM), doxorubicine (DOX; 0.5 µM), mitoxantrone (MITO; 0.25 µM), epirubicine (EPI;
0.4 µM) and etoposide (ETO; 3 µM) for 72 hours; mean of 9 data points from 3 independent experiments in
triplicates is shown; +/- standard error; Welch’s correction war required in two-tailed unpaired t-test for ALL-265
and DAU stimulation in ALL-199.
(G) 14 days after transplantation, LRC or non-LRC were isolated and 500-800 cells stimulated ex vivo for 48
hours with the following cytotoxic drugs: doxorubicine (DOX; 500 nM), epirubicine (EPI; 500 nM); etoposide
(ETO; 30 µM) and vincristine (VCR; 300 nM). Specific cell death was determined after 48h by forward-side
scatter and by DAPI staining and specific cell death calculated thereof; mean of 6 data points from 2 independent
experiments in triplicates is shown +/- standard error; ns = not significant by two-tailed unpaired t-test.
Supplemental Experimental Procedures 
 
The NSG mouse model of individual ALL 
ALL blasts were obtained from children and adults treated within clinical multicenter studies. NSG mice (NOD/scid, 
IL2 receptor gamma chain knockout mice) were obtained from The Jackson Laboratory (Lund, Sweden). The animal 
model was performed as described (Liem et al., 2004). Briefly, fresh primary ALL cells were isolated by Ficoll 
gradient centrifugation from peripheral blood or bone marrow aspirates that had been obtained from leftovers of 
clinical routine sampling before onset of therapy. 10 million ALL cells were injected into 6-12 weeks old NSG mice 
via the tail vein. Engraftment was monitored by 2-weekly flow cytometry measurement of human cells in peripheral 
blood starting at week 6. ALL-265 was first engrafted by Jean Pierre Bourquin and Beat Bornhäuser in Zurich. Mice 
were sacrificed at first clinical signs of disease, as measured by quantification of human cells in peripheral blood or 
by in vivo imaging. From engrafted mice, PDX ALL cells were harvested from enlarged spleens and either directly 
re-injected or frozen at -190 °C and re-injected after thawing. Accuracy of sample identity was verified by repetitive 
finger printing using PCR of mitochondrial DNA (Hutter et al., 2004).  
 
Cloning 
The construct encoding for all 3 transgenes (Figure S1A) was generated by cloning a synthesized DNA-fragment 
(Eurofins Scientific, Luxembourg) encoding for mKate and a truncated form of the human nerve growth factor 
receptor lacking any intracellular signaling domain (NGFR; construct -mKateT2A-NGFR) into the pCDH-EF1α-
extGLucT2A-copGFP Vector (Terziyska et al., 2012), leaving membrane anchored Gaussia luciferase and replacing 
copGFP gene using BamHI and SalI; T2A or P2A self-cleaving peptides enabled equimolar expression of the 
transgenes. For immunohistochemistry, cells were additionally transduced with a construct expressing mCherry 
which was obtained by amplifying mCherry from the pSicoR-U6-EF1a-mCherry Vector (addgene, Cambridge, MA, 
USA) and cloning it into the pCDH-EF1α-extGluc-T2A-copGFP Vector replacing the copGFP gene using BamHI 
and SalI.  
 
Lentiviral transduction of ALL PDX cells and enrichment of transgenic cells 
ALL-199 and ALL-265 were transduced using pCDH-EF1α-extGlucT2A-mKate-NGFR. Third generation packaging 
plasmids pMDLg/pRRE, pRSV-Rev and pMD2-G (Dull et al., 1998) were kindly provided by T. Schroeder. High-
titer vesicular stomatitis virus (VSV) G protein-pseudotyped lentivector was prepared by transient 4-plasmid 
transfection of 293T cells using TurboFect Transfection Reagent (Thermo Scientific, Waltham, MA, USA) and 
supernatant concentration as described (Klier et al., 2008; Terziyska et al., 2012). The functional titer of virus was 
determined by transduction of NALM-6 B-ALL cell line cells with serial dilutions of the vector stock, followed by 
analysis of transgene positive cells using flow cytometry. 
Generation of transgenic PDX cells was performed as previously described (Terziyska et al., 2012). In brief, PDX 
cells were transduced over night with lentivirus at MOI > 10 in the presence of 8 µg/ml polybrene. The next day, 
cells were washed thoroughly and injected into mice. After passaging, cells expressing the transgenes were enriched 
in two consecutive rounds by flow cytometry using FACSAriaIII (BD Biosciences) and gating on the red 
fluorochrome before cell re-amplification in mice. Although lentiviral transduction could in principle alter cells due 
to the transduction process or genomic integration, we could not detect adverse effects so far in comprehensive 
quality controls (Terziyska et al., 2012).  
 
Bioluminescence in vivo imaging 
For bioluminescence in vivo imaging mice were anesthetized with isoflurane and D-Luciferin (BIOMOL GmbH, 
Hamburg, Germany) dissolved in sterile PBS was used as substrate. Immediately after intravenous tail vein injection 
of 150 mg/kg of native D-Luciferin per mouse, mice were imaged for 30 seconds or up to 2 minutes using a field of 
view of 12.5 cm with binning 8, f/stop 1 and open filter setting using the IVIS Lumina II Imaging System (Perkin 
Elmer, MA, USA). The Living Image software 4.x (Perkin Elmer, MA, USA) was used for data acquisition and 
quantification of light emission using a scale with a minimum of 1.8×104 photons per second per cm2 per solid angle 
of 1 steradian (sr) (Terziyska et al., 2012). Mice were considered positive for engraftment, if light emission by the 
entire mouse exceeded 5x105 photons s-1 and positive signals were detected at typical sites at the lower extremities. 
 
Reagents 
For flow cytometry, analysis of NGFR, mKate, mCherry, BrdU, Annexin V, DAPI and PI was performed by flow 
cytometry, using BD LSRFortessa and BD FACSAriaIII (BD Biosciences, Heidelberg, Germany). The following 
antibodies were used: NGFR-PerCP-Cy5.5 (Biolegend, CA, USA), BrdU-APC, Annexin V-FITC detection kit (both 
  
from BD Biosciences, Heidelberg, Germany). Mouse CD45-APC-Cy7 (Biolegend, San Diego, CA, USA) was used 
to exclude mouse cells. 
BrdU incorporation was detected using the BrdU Flow Kit (BD Biosciences, Heidelberg, Germany). For analysis of 
cell viability, DAPI and/or PI were added to the cells at a concentration of 1µg/ml. All antibodies and reagents were 
used according to the manufacturer’s instructions. 
For chemotherapy treatments in vivo and ex vivo vincristine (VCR; Merck, Darmstadt, Germany), etoposide (ETO; 
Sigma Aldrich, St. Louis, USA), cyclophosphamide (Cyclo; Baxter, USA), epirubicine (EPI; Sigma Aldrich, St. 
Louis, USA), amsacrine (Amsa, Sigma Aldrich, St. Louis, USA), cytarabine (Ara-C; cell pharm GmbH, Bad Vilbel, 
Germany), daunorubicin (DAU; Sigma Aldrich, St. Louis, USA), mitoxantrone (MITO; Sigma Aldrich, St. Louis, 
USA) or doxorubicin (DOX, Sigma Aldrich, St. Louis, USA) were used. 
 
Labeling of PDX cells with BrdU and CFSE 
To label PDX cells with BrdU, donor mice were fed with BrdU (VWR, Radnor, PA, USA) during the 7 last days 
before cell isolation, at approximately 0.8 mg/kg/d BrdU using BrdU-containing drinking water. Freshly isolated 
PDX cells were labeled with CFDASE (Life Technologies, Carlsbad, CA, USA) according to manufacturer’s 
instructions. Cells were washed and directly injected into recipient mice. The procedures resulted in both BrdU and 
CFSE positivity of well above 98% of PDX cells, as validated by flow cytometry. As PDX ALL cells are 
heterogeneous in size, loss of CFSE appears as continuum in flow cytometry devoid of the distinct peaks known 
from normal lymphocytes.  
 
Enriching human PDX ALL cells from murine bone marrow 
The aim was to isolate and enrich minute numbers of human PDX ALL cells out of a major excess of murine bone 
marrow cells. The procedure was designed according to published protocols for isolating normal mouse 
hematopoietic stem cells from murine bone marrow (Takizawa et al., 2011). Our studies concentrated on the first 3 
weeks of ALL growth in mice, when low tumor burden is mainly restricted to bone marrow without major 
involvement of further organs (data not shown). 
Isolation of bone marrow cells from mice 
To collect as many bone marrow cells as possible from each mouse, the hip, femura, tibiae, spine and sternum were 
isolated and crushed in a porcelain mortar. The suspension was washed with cold PBS, filtered through a 70 µm cell 
strainer, washed again with PBS and re-suspended in cold PBS at 1x107 cells/ml.  
 
Step 1: Enriching NGFR expressing PDX cells from the bone marrow suspension 
A first enrichment step consisted in magnetic cell separation (MACS) of NGFR-expressing PDX ALL cells from the 
entire mouse bone marrow isolated. 20 µl per 1x107 cells of anti-human NGFR MicroBeads (Miltenyi Biotech, 
Bergisch Gladbach, Germany) were added to the isolated mouse bone marrow cell suspension and incubated 10 
minutes at 4°C. A maximum of 2x108 cells were loaded onto a LS column (Miltenyi Biotech, Bergisch Gladbach, 
Germany), prepared according to manufacturer’s instructions. Cells were recovered from the column according to 
manufacturer’s instructions and washed with PBS.  
 
Step 2: Enriching and quantifying fluorochrome expressing PDX cells from NGFR-expressing cells 
The second consecutive enrichment step consisted in flow cytometry enrichment of red fluorochrome expressing 
cells out of the cell suspension obtained after MACS enrichment. Cells obtained after MACS enrichment were 
stained with DAPI to exclude dead cells and with anti-muCD45-APC-Cy7 (anti-mouse CD45) to exclude murine 
hematopoietic cells. Cells were quantified and sorted using a BD FACSAriaIII (BD Biosciences, Heidelberg, 
Germany), gating (i) on the lymphocyte gate in forward/side scatter, (ii) the negative gate for both mouse CD45 and 
DAPI and ultimately (iii) the positive gate for the red fluorochrome.  
Alternatively and to quality control for the MACS enrichment step, 10% of the entire population of bone marrow 
cells was directly analyzed by flow cytometry without prior MACS enrichment and with the identical staining 
procedure (Figure S1D). The disadvantage of this procedure lies in the prolonged periods of time required for flow 
cytometric cell enrichment disabling measuring more than 10% of all cells. 
 
Enriching dormant cells (LRC) from human PDX ALL cells 
Step 3: Separating PDX ALL cells into LRC and non-LRC  
Separating PDX ALL cells into LRC and non-LRC was performed within the flow cytometry enrichment step 
described above (Step 2) by addition of a 4th gating strategy. Additionally to gating on (i) the lymphocyte gate in 
  
forward/side scatter, (ii) the negative gate for both mouse CD45 and DAPI and (iii) the positive gate for the red 
fluorochrome, gating (iv) on CFSE was used to discriminate LRC and non-LRC as shown in Figure 1D. To set gate 
4, CFSE intensity was measured at day 3 after injection when major bleaching had stopped; maximum CFSE MFI 
was used to define start of any cell proliferation (“0 divisions”). Maximum CFSE MFI was divided by factor 2 to 
calculate CFSE bisections mimicking cell divisions. 7 CFSE MFI bisections or more were defined as entire loss of 
the CFSE signal characterizing non-LRC. The LRC gate was set to include all cells harboring high CFSE signal of 
below 3 bisections of the maximum CFSE MFI (Schillert et al., 2013) (Figure 1D). All further analyses were done 
and analyzed with the same instrument settings and gates as determined using the sample on day 3 sample of the 
experiment. 
 
Ex vivo culture of PDX cells 
PDX cells were cultured in RPMI medium supplemented with 20% FSC, 1% pen/strep, 1% gentamycin, 6 mg/l 
insulin, 3 mg/l transferrin, 4 µg/l selenium (ITS-G, Gibco, San Diego, CA, USA), 2 mM glutamine, 1 mM sodium 
pyruvate, 50 µM α-thioglycerol (Sigma-Aldrich, St. Louis, MO, USA). 
 
Limiting dilution transplantation assay (LDTA) 
For LDTAs, NSG mice were injected intravenously with different amounts of PDX cells from ALL-265 or ALL-
199. Development of leukemia was monitored by bioluminescence in vivo imaging every 7 to 14 days after cell 
injection. LIC frequencies were determined according to Poisson statistics, using the ELDA software application 
(http://bioinf.wehi.edu.au/software/elda/) (Hu and Smyth, 2009). 
 
Drug stimulation ex vivo 
500 LRC and 500 or 100,000 non-LRC were cultured in 100 µl medium in 96-well plates, in cell concentrations of 
5,000 cells/ml or 106 cells/ml. Cytotoxic drugs were added in triplicates at the clinically relevant concentrations 
described in each Figure legend. Cell death was measured after 48h by forward-side scatter and DAPI or propidium 
iodide staining in a flow cytometer. Specific cell death induced by each drug was calculated as follows: specific cell 
death = [(cell death(stimulated) – cell death(control) / (100 – cell death(control))] * 100. 
For co-cultures, MS-5 cells stably expressing mtagBFP as blue fluorochrome were irradiated in suspension with 60 
Gy and seeded at 104 per well in a 96 well plate; 700 - 1,900 freshly isolated PDX cells were incubated with and 
without feeder cells in 100 µl medium for 24-48h stimulated with conventional cytotoxic drugs at clinically relevant 
concentrations; entirely all cells of each well were removed using trypsin digestion and stained with propidium 
iodide; feeder cells were excluded by gating on non-blue-expressing cells independently from CFSE or propidium 
iodide staining; absolute numbers of living PDX cells were measured using forwardside scatter analysis and cell 
death was additionally measured by propidium iodide staining in flow cytometry. 
 
In vivo treatment of mice 
For treatment of LRC, NSG mice were injected i.v. with 1x107 PDX cells. 7 days after cell injection, control animals 
received physiological salt solution i.p., while treatment group mice were injected with chemotherapeutic drugs as 
indicated in Figure legends. Mice were taken down 3 days later, bone marrow was collected, and PDX cells were 
isolated and analyzed for CFSE label retention. For calculation of relative drug effect on LRC compared to non-LRC 
(Figure 4D), first absolute number of control LRC or non-LRC were divided by the absolute number of treated LRC 
or non-LRC, respectively. In a second step, relative cell reduction in non-LRC was set to 100% and cell reduction in 
LRC was calculated relative to non-LRC. A maximum of 4 animals could be included into the same experiment as a 
maximum of 4 animals could be analyzed for CFSE distribution at the same day. 
To obtain cells at minimal residual disease, 1x106 ALL-199 or ALL-265 were injected into 19 NSG mice and 
leukemic growth was followed by weekly in vivo imaging. Treatment was started at an average of 1x1011 photons s-1, 
when untreated cells were recovered from 5 mice. Mice were divided into different treatment groups which were 
treated as indicated in Figures legends. 
 
Immunostaining of bone marrow sections 
Mouse femurs were fixed in zinc formalin fixative for 1 day at 4°C. Bones were washed with PBS and decalcified 
with Osteosoft (Merck) for 3 days at 4°C, infiltrated with 30% sucrose for 1 day at 4°C, embedded in O.C.T. 
compound (Sakura) and stored at -80°C. Cryosections of decalcified bones were obtained by using the CryoJane tape 
transfer system (Leica). For immunostaining, sections were permeabilized and blocked with 5% goat serum and 
0.1% Tween-20 serum in PBS for 45 min at room temperature. Primary antibodies were applied for 1 day at 4°C and 
  
followed by secondary antibody incubation for 45 min at room temperature. Sections were finally stained with 10 
mg/ml DAPI for 15 min and the slides were mounted with prolong gold (Invitrogen). Washing in between each 
staining steps was performed. Primary antibodies were rabbit-anti-FITC (ThermoFisher; 1:100) and rabbit-anti-
mCherry (Abcam; 1:100) and goat-anti-rabbit with Alexa 594 (Invitrogen) was used as secondary antibody. Images 
were acquired on a Leica SP5 confocal microscope and analyzed with ImageJ. CFSE signal intensity was adapted to 
the mCherry signal by adjusting the 8 bit threshold for quantification of the LRC population based on FACS data. 
The endosteal region was defined as less than 100 µm from bone matrix (Nombela-Arrieta et al., 2013). Cells of 
interests were counted semi-automatically by the program ImageJ. Relative endosteal cells were calculated as 
absolute cell numbers in the endosteal region divided by absolute cell numbers in entire bone marrow section. Mean 
and standard error were calculated from at least 3 sections of each femur from 2 independent mice.  
For immunhistology of primary bone marrow biopsies, bone marrow biopsies were fixed and stained using the 
avidin-biotin-peroxidase complex (ABC) method (Hsu et al., 1981) and anti-TdT antibody (Leica, Germany) and 
anti-Ki-67 antibody (Dako, Germany).  
 
Flow cytometric cell enrichment of StemB cells from BCR-ABL positive ALL 
Thawed mononuclear bone marrow cells were handled on ice and stained with CD3-FITC, CD19-PE, CD34-APC, 
CD38-PECy7 (all Becton Dickinson) and DAPI 0.1 µg/ml; StemB cells expressing CD3- CD34+ CD38-/low CD19+ 
cells were enriched using the FACSAriaTM (Becton Dickinson) according to (Castor et al., 2005; Hong et al., 2008; 
Lutz et al., 2013). 
 
Flow cytometric cell enrichment of diagnostic and MRD pediatric BCP-ALL cells 
Thawed mononuclear bone marrow cells were handled on ice and stained using antibodies appropriate for minimal 
residual disease (MRD) detection against CD10, CD19, CD20, CD34, CD38, CD45, CD58, CD99, and CD123. 
Leukemic blasts were enriched to >95% purity using a FACSAria™ Fusion cell sorter equipped with an automatic 
cell deposition unit (ACDU; Becton Dickinson); data analysis was performed using the FACSDiva™ software 
(Becton Dickinson).  
 
Bulk RNA sequencing library construction 
PDX LRC and non-LRC cell populations were sorted into lysis buffer composed of 0.2 % Triton X-100 (Sigma) and 
2 U/µl of RNAse Inhibitor (Life Technologies). ERCC spike-in controls (Life Technologies) were added to the cell 
lysis mix at 1:5,000 dilution. RNA was cleaned-up from the crude lysate with Agencourt RNAclean XP SPRI beads 
(Beckman-Coulter). cDNA was synthesized and pre-amplified from 5 µl of lysate according to the Smart-seq2 
protocol (Picelli et al., 2013).  
For each pediatric ALL MRD and PDX MRD sample, 2000 cells were sorted into TCL buffer (Qiagen). RNA was 
cleaned up using Agencourt RNAclean XP SPRI beads from half of the lysate and used to generate UMI-seq 
libraries as previously described (Parekh et al., 2016). 
For all libraries, 1 ng of pre-amplified cDNA was used as input for tagmentation by the Nextera XT Sample 
Preparation Kit (Illumina), where a second amplification round was performed for 12 cycles.  
 
RNA sequencing library construction of primary StemB single cells 
Single adult StemB cells were deposited in 96-well plates containing 5 µl lysis buffer composed of a 1:500 dilution 
of Phusion HF buffer (NEB).  Single-cell RNA-seq libraries were constructed using the SCRB-seq method according 
to (Soumillon et al., 2014).  
 
RNA-seq analysis 
All sequencing reads were demultiplexed from the Nextera (i5 and i7) indices. 
For Smart-seq libraries, demultiplexed reads were aligned to the human genome (hg19) and ERCC reference using 
NextGenMap (Sedlazeck et al., 2013). Count data was generated from mapped reads using featureCounts (Liao et al., 
2014) on ENSEMBL gene models (GRCh38.74). 
For UMI-seq and SCRB-seq libraries, read pairs were processed by tagging the cDNA read with barcode and UMI 
sequences using the Drop-seq tools pipeline (Macosko et al., 2015). Tagged reads were aligned to the human genome 
(hg19) using STAR (Dobin et al., 2013) and sample-wise count tables generated using Drop-seq tools.  
 
To remove noise from lowly expressed genes, count data sets were subjected to data-driven gene filtering using the 
HTSFilter R package (Rau et al., 2013). For PDX single cell sequencing libraries, only those cell data sets were used 
  
which came from viable cells, obtained at least 1 million reads and detected at least 3000 genes (TPM > 1). For 
combined bulk (1x ALL-265; 4x ALL-265) and single cell (1x ALL-265) analysis (Figure 5), filtered single cell 
datasets were included summarized by gene-wise median read count as one LRC and non-LRC replicate. Differential 
expression (DE) analysis was done in the DESeq2 R package (Love et al., 2014) using the Wald test. 
A combined LRC signature (ALL-265 & ALL-199; 250 genes; FC > 1; padj < 0.05) was obtained from this data.  
Overrepresentation of significantly differentially expressed genes in KEGG pathways was tested by a fixed network 
enrichment analysis (FNEA) implemented in the neaGUI R package (Alexeyenko et al., 2012). 
We applied hierarchical clustering gene-wise and sample-wise with complete linkage based on Euclidian distances of 
variance stabilized counts of DE genes (500 genes with lowest padj, FDR adjustment  (Benjamini and Hochberg, 
1995)) and plotted as heatmap. The reference expression value is the expression average of non-LRC cells. 
Principal Component Analysis (PCA) of LRC PDX cells was performed on variance stabilized counts of the 500 
most variable genes to display the main variance of the samples. 
To analyse combined data from all obtained single-cells, count data was normalized accounting for batch effects 
using SCONE (Risso et al., 2014). PCA and k-means clustering of combined single-cell data was performed on all 
shared detected genes. 
Gene set enrichment analysis was performed using GSEA Desktop Application. For ranking all genes, a metric score 
was calculated by multiplying their log fold changes with the –log10(p_adj) values and submitted to the Pre-Ranked 
GSEA tool. The statistical significance was determined by 1000 gene set per mutations (Subramanian et al., 2005). 
 
Dynamical modelling 
The growth behavior of ALL cells in bone marrow has been analyzed using mechanistic ordinary differential 
equation models describing the population growth and the CFSE dilution. To gain insights into the in vivo growth 
behavior of ALL cells, we compared three alternative models. The first model assumed exponential growth, the 
second model assumed logistic growth caused by a decreased rate of cell division at higher cell densities, and the 
third model assumed logistic growth caused by an increased rate of cell death at higher cell densities. 
The state variables of all three models are the cell number n(t) and the mean fluorescence intensity m(t). The 
governing equations for n(t) and m(t), 
dn/dt = (α(n)-β(n)) n, N(0) = n0,  
dm/dt = - (α(n)+k) m, m(0) = m0, 
have been deduced from existing partial differential equation models (Hasenauer et al., 2012). In this governing 
equations α(n) denotes the rate of cell division, β(n) denotes the rate of cell death, and k denotes the rate of CFSE 
degradation. 
The three model alternatives only differed in the parameterization of rates of cell division and cell death, α(n) and 
β(n). For the exponential growth model all rates were constant, α(n) = α0 and β(n) = β0. For the logistic growth 
model with decreasing cell division at higher cell densities α(n) = α0 (1-n/nα) and constant β(n) = β0 were used. For 
the logistic growth model with increasing cell death at higher cell densities constant α(n) = α0 and β(n) = β0 (1+n/nβ) 
were used. As the measurement of the mean intensity induced by CFSE is corrupted by the cell’s autofluorescence, 
we measure m’(t) = m + ma, in which ma denotes the average autofluorescence. 
The parameters of the three models were determined from measurement of n(t) and m’(t) using maximum likelihood 
estimation, assuming normally distributed measurement noise. For model comparison the Akaike information 
criterion (AIC) was used. 
 
Statistics 
All statistical analyses were calculated using GraphPad Prism 6 software. Two-tailed unpaired t-test was applied to 
evaluate differences after drug treatment. F-test was applied to compare standard deviations; in cases, when standard 
deviations differed significantly, Welch’s correction was applied. LIC frequencies were calculated according to 
Poisson statistics using the ELDA software application (http://bioinf.wehi.edu.au/software/elda) (Hu and Smyth, 
2009). 
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